These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 11983097)

  • 1. Nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Baron F; Beguin Y
    J Hematother Stem Cell Res; 2002 Apr; 11(2):243-63. PubMed ID: 11983097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minitransplants: allogeneic stem cell transplantation with reduced toxicity.
    Beguin Y; Baron F
    Acta Clin Belg; 2003; 58(1):37-45. PubMed ID: 12723260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine.
    Carella AM
    Hematol J; 2004; 5 Suppl 1():S68-75. PubMed ID: 15079155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nonmyeloablative stem cell transplantation as cancer immunotherapy].
    Willems E; Baron F; Vanstraelen G; Frère P; Fillet G; Beguin Y
    Rev Med Suisse; 2005 Aug; 1(30):1973-7. PubMed ID: 16200942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.
    Champlin R; Khouri I; Anderlini P; Gajewski J; Kornblau S; Molldrem J; Shimoni A; Ueno N; Giralt S
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S13-22. PubMed ID: 11436116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-myeloablative transplants for malignant disease.
    Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
    Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells.
    Baron F; Baudoux E; Frère P; Tourqui S; Schaaf-Lafontaine N; Greimers R; Herens C; Fillet G; Beguin Y
    J Hematother Stem Cell Res; 2002 Apr; 11(2):301-14. PubMed ID: 11983101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Georges GE; Storb R
    Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmyeloablative allogeneic stem cell transplantation for acute leukemia.
    Laport GG
    Curr Hematol Rep; 2003 Jan; 2(1):49-56. PubMed ID: 12901154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia.
    Qazilbash MH; Giralt SA; Champlin RE
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):703-13, xi. PubMed ID: 15271401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
    Banna GL; Aversa S; Sileni VC; Favaretto A; Ghiotto C; Monfardini S
    Crit Rev Oncol Hematol; 2004 Sep; 51(3):171-89. PubMed ID: 15331077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience.
    Shimoni A; Nagler A
    Curr Hematol Rep; 2004 Jul; 3(4):242-8. PubMed ID: 15217553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-myeloablative transplantation.
    Maloney DG; Sandmaier BM; Mackinnon S; Shizuru JA
    Hematology Am Soc Hematol Educ Program; 2002; ():392-421. PubMed ID: 12446434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
    Giralt S
    Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.